Research & Development
We have, since our inception, set our strategic focus on major therapeutic areas with substantial unmet medical needs.
10
In-house/co-developed novel antibodies
2020
plan to file first NDA
3
NDAs to file in next 18 months
18
Clinical trials ongoing
Multiple
INDs in next 12-18 months

World Class R&D expertise

Cutting-edge antibody and cell therapy plassforms

Global clinical development capabilities

Global cGMP-compliant manufacturing capabillities

Collaborations and partnerships in China and globally

Deep China experience to drive commercial rollout